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tion of the Centre’s activities, for each modality of pa-
tient follow-up and treatment (surgery, radiotherapy,
chemotherapy, consultations). Unit costs were obtained
from cost accounts of the Centre. Medical cost of breast
cancer was computed from the cancer-centre perspective,
by adding micro-costing and macro-costing components.
RESULTS: The mean medical cost per patient was €10
072 [95% CI 9 195; 10 948]. Costs per patient ranged
from €2 813 to €36 170. Median cost was of €8 860.
The initial treatment phase represented the most expen-
sive component, reaching €7 378 [7 040; 7 717] on aver-
age, which amounted to 73.3% of the global cost.
CONCLUSION: This study has provided an estimate of
the global cost of managing patients with breast cancer in
a French Comprehensive Cancer Centre (CLCC). Our es-
timates were consistent with those of the French national
database of costs per DRG. However, our approach has
the advantage of providing a cost per patient suitable for
cost-of-illness evaluations, rather than a cost per hospital
stay.
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OBJECTIVE: To compare the pharmacoeconomic results
of a breast cancer treatment model for Japan using sev-
eral criteria, including level of evidence of the clinical
data.
METHODS: The Japanese Breast Cancer Treatment
Model (JBCTM) features treatment pathways for four
breast cancer stages. The model includes resources, costs,
and clinical outcomes for all treatments, and has the abil-
ity to estimate the cost-effectiveness of treatments in vari-
ous settings with consideration given to the level of evi-
dence. Guidelines from the American Society of Clinical
Oncology (ASCO) were used to stratify the clinical data
for drug treatments in the model. The ASCO levels of ev-
idence criteria are ranked from Level I, evidence from
studies showing the highest level of clinical results sup-
porting treatment usage, to Level V, those yielding the
weakest evidence for usage. For the JBCTM, the ASCO
definitions of Levels I and II were directly followed and
Levels III through V were combined into one level. The
model contains over 450 level-of-evidence references for
more than 60 drug treatments. An example of an evalua-
tion using the JBCTM is a cost-effectiveness analysis com-
paring one chemotherapy combination, CAF, to two other
regimens, CEF and CMF in advanced breast cancer.
RESULTS: Although the incremental cost-effectiveness
ratio for CAF compared to CEF is negative, indicating
CAF is a dominant strategy, the clinical evidence is only
Level II. In contrast, the incremental cost-effectiveness ra-
tio for CAF compared to CMF is positive, although rela-
tively low at 14,087¥ for each percentage increase in ob-
jective response, but the clinical evidence is Level I, the
highest possible.
CONCLUSIONS: Although the cost-effectiveness ratios
show that CAF is more cost-effective when compared to
CEF than when compared to CMF, the evidence level for
choosing CAF over CMF is higher. Decision-makers can
be more informed by considering both levels of evidence
and pharmacoeconomic data.
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OBJECTIVES: Hyperuricemia (HU) and tumour lysis
syndrome (TLS) are important complications leading to
morbidity and mortality in patients with haematologic
malignancies. The objective was to assess the cost-effec-
tiveness (CE), in terms of cost per life year saved (LYS),
of preventing or treating HU and TLS with recombinant
urate oxidase, rasburicase (FASTURTEC®).
METHODS: The current incidence and costs of HU and
TLS were studied in a multi-country chart review includ-
ing 788 adults and children treated for acute lymphoid or
myeloid leukaemia (ALL or AML) or non-Hodgkin lym-
phoma (NHL). Costs, expressed in Euro, were calculated
from the UK payer’s perspective. The average life expect-
ancy at the time of diagnosis was based on cancer sur-
vival rates and age at diagnosis reported in the literature.
Adult data were derived from the Eurocare study, child-
hood data from UK national statistics.
RESULTS: HU incidence was 18.9% and its average cost
was 1,679Euro (SE  519). TLS incidence was 5% and
its average cost was 11,202Euro (SE  2,147), and TLS-
related mortality was 0.8%. With 90% reduction of HU
and 100% reduction of TLS cases by rasburicase, the av-
erage CE of prevention in adults was 20,652Euro/LYS
for ALL, 83,824 Euro/LYS for AML and 31,667 Euro/
LYS for NHL. The high CE ratio in AML is explained by
its low life expectancy. In children the respective results
were only 379 Euro/LYS, 668 Euro/LYS, and 388 Euro/
LYS. Sensitivity analyses showed these results to be ro-
bust, especially in children. If applied only for treatment
of established HU/TLS, rasburicase is associated with
savings of 1,089 Euro in adults and 2,358 Euro in chil-
dren, becoming cost-saving as of a 65% and only 24%
reduction of TLS in adults and children respectively.
CONCLUSION: In prevention of HU/TLS, highly cost-
effective results can be obtained in children, and reason-
ably cost-effective results in adults with ALL. Both in
adults and children, treating HU with rasburicase would
be a cost saving intervention.
